TINEA
MCID: DRM011
MIFTS: 52

Dermatophytosis (TINEA)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 73 15 70 32
Tinea 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD9CM 34 110
NCIt 50 C26745
SNOMED-CT 67 154394006
ICD10 32 B35 B35.9
UMLS 70 C0011636 C0040247

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea unguium and candidiasis, familial, 2, and has symptoms including fever, pruritus and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Innate Immune System and CLEC7A (Dectin-1) signaling. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include scalp, glabrous skin and nail, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
# Related Disease Score Top Affiliating Genes
1 tinea unguium 32.3 TRIR SQLE
2 candidiasis, familial, 2 32.1 CLEC7A CARD9
3 tinea profunda 32.1 CLEC7A CLEC6A CLEC4E CARD9
4 tinea corporis 32.0 SQLE DEFB4A CLEC7A CLEC6A CLEC4E CARD9
5 tinea cruris 31.7 TRIR SQLE DEFB4A CYP51A1 CLEC6A CARD9
6 tinea pedis 31.3 TRIM4 SQLE DEFB4A CYP51A1 CLEC7A CLEC6A
7 dermatomycosis 31.2 POLR2B CYP51A1 CLEC7A CD4
8 superficial mycosis 30.9 POLR2B CLEC7A CLEC6A CLEC4E CD4
9 folliculitis 30.5 DEFB4A CD4 CCR6
10 pityriasis versicolor 30.4 SQLE CLEC7A CLEC6A CLEC4E
11 tinea capitis 30.3 SQLE SLC7A1 POLR2B ELOA3BP CLEC7A CLEC6A
12 fungal keratitis 30.3 CLEC7A CLEC4E
13 cellulitis 30.1 DEFB4A CD4 CCR6
14 candidiasis 30.1 STAT1 IL17A DEFB4A CYP51A1 CLEC7A CARD9
15 pustulosis of palm and sole 30.1 IL17A CCR6
16 keratitis, hereditary 30.0 IL17A CD4 CCR6
17 dermatitis 30.0 STAT1 IL17A DEFB4A CD4 CCR6
18 aspergillosis 30.0 CSF1 CLEC7A CCR6
19 seborrheic dermatitis 29.9 DEFB4A CD4 CCR6
20 chickenpox 29.9 STAT1 CD4 CCR6
21 keratoconjunctivitis sicca 29.9 LTF CD4 CCR6
22 leprosy 3 29.9 IL17A CD4 CCR6
23 contact dermatitis 29.8 IL17A DEFB4A CD4 CCR6
24 langerhans cell histiocytosis 29.8 IL17A CSF1 CCR6
25 chromoblastomycosis 29.8 CLEC7A CLEC6A CLEC4E CCR6 CARD9
26 nocardiosis 29.8 IL12RB1 CD4
27 immunodeficiency 31b 29.7 STAT1 IL12RB1
28 t cell deficiency 29.7 IL17A CD4 CCR6
29 cutaneous candidiasis 29.6 IL17A CLEC7A CLEC6A CCR6 CARD9
30 bacterial infectious disease 29.6 LTF IL17A DEFB4A CD4 CCR6
31 allergic contact dermatitis 29.5 IL17A DEFB4A CD4 CCR6
32 immune deficiency disease 29.5 STAT1 IL17A IL12RB1 CSF1 CD4 CCR6
33 disease by infectious agent 29.5 IL17A DEFB4A CD4 CCR6
34 pneumocystosis 29.5 CLEC7A CLEC4E CD4 CCR6 CARD9
35 dermatitis, atopic 29.3 IL17A IL12RB1 DEFB4A CD4 CCR6
36 mucormycosis 29.2 CYP51A1 CLEC7A CLEC6A CD4 CCR6 CARD9
37 oral candidiasis 29.0 STAT1 LTF IL17A DEFB4A CLEC7A CLEC6A
38 chronic mucocutaneous candidiasis 28.6 STAT1 IL17A IL12RB1 CSF1 CLEC7A CLEC6A
39 fungal infectious disease 28.4 STAT1 POLR2B IL17A IL12RB1 DEFB4A CYP51A1
40 nail disease 28.3 STAT1 IL17A IL12RB1 CLEC7A CLEC6A CLEC4E
41 deep dermatophytosis 11.3
42 tinea manuum 11.3
43 tinea barbae 11.2
44 alopecia 10.4
45 skin disease 10.3
46 baritosis 10.3 STAT1 CSF1
47 haemophilus influenzae 10.3 LTF CLEC7A
48 geotrichosis 10.3 STAT1 CD4
49 tinea imbricata 10.3
50 adenoiditis 10.3 CLEC7A CARD9

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


fever; pruritus; exanthema

GenomeRNAi Phenotypes related to Dermatophytosis according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.16 TRIR
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.16 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.16 TRIR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.16 CLEC7A TRIR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.16 CLEC7A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.16 CLEC7A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.16 CLEC7A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.16 IL17A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.16 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.16 TRIR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.16 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.16 CLEC7A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-15 10.16 SLC7A1 TRIR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.16 TRIR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.16 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.16 CLEC7A TRIR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.16 CLEC7A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.16 TRIR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.16 CLEC7A SLC7A1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.16 SLC7A1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.16 TRIR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.16 TRIR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.16 CLEC7A IL17A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.16 TRIR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.16 CLEC7A IL17A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.16 IL17A
27 Reduced mammosphere formation GR00396-S 9.17 CCR6 CLEC7A CSF1 CYP51A1 IL17A POLR2B

MGI Mouse Phenotypes related to Dermatophytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CARD9 CCR6 CD4 CLEC4E CLEC6A CLEC7A
2 immune system MP:0005387 9.44 CARD9 CCR6 CD4 CLEC4E CLEC6A CLEC7A

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
4
Naftifine Approved Phase 4 65472-88-0 73342 47641
5
Luliconazole Approved Phase 4 187164-19-8
6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
7
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
8
Efinaconazole Approved Phase 4 164650-44-6
9 Anti-Infective Agents Phase 4
10 Antifungal Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Anti-Ulcer Agents Phase 4
13 Antacids Phase 4
14 Proton Pump Inhibitors Phase 4
15 Selenium disulfide Phase 4
16 Pharmaceutical Solutions Phase 4
17
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
18
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
19
Ciclopirox Approved, Investigational Phase 3 29342-05-0 2749
20
Griseofulvin Approved, Investigational, Vet_approved Phase 3 126-07-8 441140
21
Econazole Approved Phase 3 27220-47-9 3198
22
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
23
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
24 Papaya Approved Phase 2, Phase 3
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
27
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
28 Trace Elements Phase 2, Phase 3
29 Micronutrients Phase 2, Phase 3
30 Tubulin Modulators Phase 2, Phase 3
31 Antimitotic Agents Phase 2, Phase 3
32 Antiparasitic Agents Phase 2, Phase 3
33 Anthelmintics Phase 2, Phase 3
34 Antiprotozoal Agents Phase 2, Phase 3
35 Anti-Infective Agents, Local Phase 3
36 Anti-Asthmatic Agents Phase 3
37 Respiratory System Agents Phase 3
38 Antiemetics Phase 3
39 glucocorticoids Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41
protease inhibitors Phase 3
42 Betamethasone Valerate Phase 3 2152-44-5
43 Betamethasone benzoate Phase 3
44 BB 1101 Phase 3
45 Anti-Inflammatory Agents Phase 3
46 Betamethasone sodium phosphate Phase 3
47 HIV Protease Inhibitors Phase 3
48 Betamethasone-17,21-dipropionate Phase 3
49
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
50
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
2 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
5 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
6 A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
7 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
8 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
9 The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial Completed NCT04007237 Phase 4 shampoo with different composition
10 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
11 Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
12 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
13 A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis. Completed NCT04203342 Phase 3 Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.);Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA);Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
14 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
15 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
16 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
17 Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
18 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
19 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
20 A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
21 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
22 An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis Completed NCT00645242 Phase 3 fluconazole
23 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
24 A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
25 Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis Completed NCT03320486 Phase 3 Dapaconazole;Ketoconazole
26 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
27 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
28 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
29 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
30 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
31 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
32 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
33 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
34 Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. Recruiting NCT02582177 Phase 3 Candicort®;Nizoral®;Baycuten N®;Canesten®
35 A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
36 Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
37 A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Unknown status NCT03471455 Phase 2 Isotretinoin;Terbinafine;Itraconazole 200 mg
38 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
39 Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Completed NCT02824926 Phase 2 Dapaconazole;Ketoconazole
40 A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis Completed NCT02860052 Phase 2 SB208 2%;SB208 4%;SB208 16%;Vehicle Gel
41 Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis Completed NCT01096472 Phase 2 LAS41003;LAS189961;LAS189962
42 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis Completed NCT01891305 Phase 2 VT-1161;placebo
43 Three-Arm Trial of Novel Treatment for Tinea Pedis Completed NCT03135912 Phase 2 Experimental Drug SESC 01;Placebo;Terbinafine Hydrochloride
44 A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot) Completed NCT02871011 Phase 2 Nitric Oxide;Water
45 A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis Completed NCT00768599 Phase 2 Econazole Nitrate Cream 1%;Econazole Nitrate Foam 1%;Vehicle Foam
46 Clinical Study Protocol Number DBI-201. Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With Tinea Pedis Completed NCT04152226 Phase 2 J. Lividum
47 A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis Completed NCT00893880 Phase 2 1% gaseous Nitric Oxide blended in Oxygen
48 A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot) Completed NCT00771342 Phase 2 Nitric Oxide;Nitrogen
49 Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis Completed NCT00869336 Phase 2 Luliconazole Cream 1% - 2 wks;Placebo Comparator -2 wks;Luliconazole Cream 1% - 4 wks;Placebo Comparator - 4 wks
50 A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years Completed NCT01696799 Phase 2 Econazole Nitrate;placebo

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

19
Scalp, Glabrous Skin, Nail

MalaCards organs/tissues related to Dermatophytosis:

40
Skin, Thymus, Pituitary, Bone Marrow, Monocytes, T Cells, Lymph Node

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 6501)
# Title Authors PMID Year
1
Development, optimization and characterization of nanoemulsion loaded with clove oil-naftifine antifungal for the management of tinea. 61
33517791 2021
2
Extensive tinea corporis caused by a virulent strain of Trichophyton interdigitale. 61
33599991 2021
3
Expression of Epidermal Antimicrobial Peptides is increased in Tinea Pedis. 61
33797129 2021
4
Molecular identification and antifungal susceptibility among clinical isolates of dermatophytes in Shiraz, Iran (2017-2019). 61
33295089 2021
5
Invasive dermatophyte infection: A systematic review. 61
33217082 2021
6
Trichoscopic signs of tinea capitis: a guide for selection of appropriate antifungal. 61
33141453 2021
7
A systematic review of worldwide data on tinea capitis: analysis of the last 20 years. 61
32976663 2021
8
Estimation of the burden of tinea capitis among children in Africa. 61
33251631 2021
9
Tinea capitis et barbae caused by Trichophyton tonsurans: A retrospective cohort study of an infection chain after shavings in barber shops. 61
33341968 2021
10
Epidemiological study of terbinafine-resistant dermatophytes isolated from Japanese patients. 61
33439506 2021
11
Epidemiological and clinical aspects of Trichophyton mentagrophytes/Trichophyton interdigitale infections in the Zurich area: a retrospective study using genotyping. 61
33411941 2021
12
A cross-sectional study on dermatoses among underwater workers: a new clinical sign of peculiar distribution pattern of lesions in sea urchin prick reaction revealed. 61
33377192 2021
13
The prevalence of dermatophytoses in Brazil: a systematic review. 61
33533707 2021
14
Antifungal activity and potential mechanism of magnoflorine against Trichophyton rubrum. 61
33082529 2021
15
Cellulitis. 61
33494874 2021
16
Validation of a lateral flow immunochromatographic assay for tinea unguium diagnosis. 61
33686693 2021
17
Letter in response to the article: "Nannizzia incurvata as a rare cause of favus and tinea corporis in Cambodia and Vietnam". 61
33666029 2021
18
Tinea corporis incognito due to Microsporum Gypseum: Report of eight cases in children. 61
33709430 2021
19
Virulence and Antifungal Susceptibility of Microsporum canis Strains from Animals and Humans. 61
33809233 2021
20
Familial Cases of Trichophyton benhamiae Infection Transmitted from a Guinea Pig in Iran. 61
33394270 2021
21
The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. 61
33769736 2021
22
Tinea capitis caused by Nannizzia gypsea after playing by a river. 61
33715912 2021
23
A Retrospective Study of Tinea Capitis Management in General Pediatric Clinics and Pediatric Emergency Departments at Two U.S. Centers. 61
33794219 2021
24
Cryptic deep dermatophytosis in a renal transplant recipient with hidradenitis suppurativa. 61
33665286 2021
25
Exfoliative dermatitis due to dermatophytosis. 61
33690216 2021
26
[Noninvasive diagnostic imaging in pediatric skin lesions]. 61
33471130 2021
27
Total serum IgE level in patients of dermatophytosis and its association with various clinical parameters. 61
33769756 2021
28
Evaluation of activity and toxicity of combining clioquinol with ciclopirox and terbinafine in alternative models of dermatophytosis. 61
33772895 2021
29
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. 61
33768571 2021
30
Dermatophytosis caused by Trichophyton benhamiae in a dog. 61
33739489 2021
31
The spectrum of pediatric scarring alopecia: A retrospective review of 27 patients seen at Mayo Clinic. 61
33644931 2021
32
Estimates of serious fungal infection burden in Côte d'Ivoire and country health profile. 61
33259981 2021
33
[Palmoplantar dermatoses in children]. 61
33580281 2021
34
Ethnopharmacology, biological activity and phytochemistry of Scaevola spinescens R. Br. 61
33719150 2021
35
Mechanism of streptomyces albidoflavus STV1572a derived 1-heneicosanol as an inhibitor against squalene epoxidase of Trichophyton mentagrophytes. 61
33811987 2021
36
Terbinafine resistance in dermatophytes: Time to revisit alternate antifungal therapy. 61
33360137 2021
37
Development of a highly persistent silicone-based sprayable emulsion containing essential oils for treatment of skin infections. 61
33493602 2021
38
Evaluation of Derma Genius® Resistance Real-Time Polymerase Chain Reaction (RT-PCR) for Rapid Detection of Terbinafine Resistant Trichophyton species. 61
33760310 2021
39
Antifungal susceptibility testing of dermatophytes: Development and evaluation of an optimised broth microdilution method. 61
33084127 2021
40
Investigation of in vitro antifungal susceptibility testing and genetic diversity of clinical isolates of Trichophyton benhamiae and Trichophyton eriotrephon in Iran. 61
33190353 2021
41
Correlation between dermoscopy and direct microscopy in Tineabarbae. 61
33388670 2021
42
Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte Trichophyton rubrum. 61
33313977 2021
43
Potentiation of antifungal activity of terbinafine by dihydrojasmone and terpinolene against dermatophytes. 61
32790923 2021
44
The Spread of Resistant Tinea and the Ingredients of a Perfect Storm. 61
33789286 2021
45
Screening Balanites aegyptiaca for inhibitors against putative drug targets in Microsporum gypseum - Subtractive proteome, docking and simulation approach. 61
33549764 2021
46
Nanoencapsulated hypericin in P-123 associated with photodynamic therapy for the treatment of dermatophytosis. 61
33383558 2021
47
[Report of the first case of tinea corporis bullosa by Trichophyton tonsurans]. 61
32820362 2021
48
Two-Year US Pharmacovigilance Report on Brodalumab. 61
33337520 2021
49
[Tinea capitis: clinical features and therapeutic alternatives]. 61
33618899 2021
50
Laboratory monitoring during antifungal treatment of paediatric tinea capitis. 61
33064847 2021

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 CLEC6A CLEC4E CARD9
2 defense response to Gram-positive bacterium GO:0050830 9.65 IL17A DEFB4A CARD9
3 cytokine-mediated signaling pathway GO:0019221 9.65 STAT1 IL17A IL12RB1 CSF1 CD4
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.62 LTF CLEC6A CD4 CARD9
5 positive regulation of interleukin-6 production GO:0032755 9.61 IL17A CLEC7A CARD9
6 positive regulation of tumor necrosis factor production GO:0032760 9.58 IL17A CLEC7A CARD9
7 innate immune response GO:0045087 9.5 TRIM4 IL17A CSF1 CLEC7A CLEC6A CLEC4E
8 regulation of tumor necrosis factor production GO:0032680 9.46 LTF CARD9
9 defense response to Gram-negative bacterium GO:0050829 9.46 LTF IL17A DEFB4A CD4
10 positive regulation of monocyte differentiation GO:0045657 9.37 CSF1 CD4
11 immune system process GO:0002376 9.28 TRIM4 LTF IL17A CSF1 CLEC7A CLEC6A

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pattern recognition receptor activity GO:0038187 8.62 CLEC7A CLEC4E

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....